Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
2.72 2.10 2.46 1.91
P/FCF ratio
29.39 21.58 19.07 14.16
P/Operating CF
60.60 205.57 67.02 36.01
P/B ratio
3.83 2.87 3.12 2.26
EV/Sales
3.33 2.71 2.94 2.41
EV/EBITDA
24.09 18.65 19.90 12.36
EV/FCF
35.94 27.90 22.78 17.81
Current Ratio
1.35 1.36 1.29 1.37
Net Debt/EBITDA
12.97 13.21 (47.87) 9.04
Debt/Equity
0.92 0.90 0.67 0.64
Earnings Yield
(2.13%) (2.17%) (1.48%) (0.99%)
Free Cash Flow Yield
3.40% 4.63% 5.24% 7.06%
Free Cash Flow per Share
3.09 (0.30) 1.18 3.62
Book value per Share
59.27 60.19 63.96 69.30
Free Cash Flow
148.62 (14.83) 58.57 178.25
EV/EBIT
147.77 155.10 469.42 68.70
Other line items

Show all line items

Columns are period end dates